Conferencias

Pancreatic

A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative oncology Group (ECOG) trial
Presenter: J. Berlin Affiliation: ECOG, USA Background: The vast majority of patients with pancreatic cancer are diagnosed with locally advanced unrespectable or advanced disease for which there is no curative therapy. Many chemotherapeutic agents have been evaluated in patients with pancreatic cancer. Gemcitabine (gem) and 5-FU are the

Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor Multicenter phase II study
Presenter: C. Louvet Affiliation: Hospital St-Antoine, Paris France Background: Gemcitabine has been shown to be an active agent in the treatment of pancreatic cancer. Some preclinical data showed that the combination of gemcitabine with oxaliplatin (GEMOX) exerts potent antiproliferative effects in human cancer cell lines, including

A Phase II Study of External Irradiation and Weekly Paclitaxel for Non-Metastatic, Unresectable Pancreatic Cancer: A Preliminary Report of RTOG Protocol 98-12
Presenter: T. Rich Affiliation: University of Virginia Type of Session: Scientific Background Unresectable/locally advanced pancreatic cancer remains a difficult disease to treat, with median survival of less than 1 year This is a new approach to the management of pancreatic cancer, using paclitaxel (Taxol) and radiation therapy to improve

Simultaneous Gemcitabine/Cisplatin and Radiotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma using a Strict GEM/RT Time Schedule. A Phase I/II Study
Presenter: T. Brunner Presenter's Affiliation: University Hospitals Erlangen, Erlangen, Germany Type of Session: Scientific Background Patients with locally advanced pancreatic cancer treated with induction chemoradiation (CRT) prior to surgery have a survival advantage as compared to patients treated with resection at diagnosis. Snady et al.

Gemcitabine, Paclitaxel, and Radiation for Locally Advanced Pancreatic Cancer: A Phase I Trial
Presenter: T. Dipetrillo Presenter's Affiliation: Brown University Type of Session: Scientific Background Locally advanced pancreatic cancer has Gemcitabine and paclitaxel are both radiation sensitizers The use of paclitaxel has demonstrated efficacy in RTOG 98-12 The feasibility of concurrent weekly paclitaxel and gemcitabine with